Related Experiment Video
Updated: Dec 10, 2025
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic
Joan How1,2,3, Gabriela S Hobbs1
1Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School.
Abstract:
Primary myelofibrosis (PMF) has the least favorable prognosis of the Philadelphia chromosome-negative myeloproliferative neoplasms, which also include essential thrombocythemia (ET) and polycythemia vera (PV). However, clinical presentations and outcomes of PMF vary widely, with median overall survival ranging from years to decades. Given the heterogeneity of PMF, there has been considerable effort to develop discriminatory prognostic models to help with management decisions, particularly for the consideration of hematopoietic stem cell transplantation in patients at higher risk. Although earlier models incorporated only clinical features in risk stratification, contemporary models increasingly use molecular and cytogenetic features, leading to more comprehensive prognostication. This article reviews the most widely adopted prognostic models used for PMF, including the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS)/DIPSS+, mutation-enhanced IPSS for transplant-age patients (MIPSS70)/MIPSS70+/MIPSS70+ version 2.0, genetically inspired prognostic scoring system, and Myelofibrosis Secondary to PV and ET-Prognostic Model in patients with post-ET/PV myelofibrosis. We also discuss newly emerging prognostic models and provide a practical approach to risk stratification in patients with PMF and post-ET/PV myelofibrosis.
Insights
Primary myelofibrosis (PMF) prognosis varies greatly. This review details key prognostic models, integrating clinical, molecular, and cytogenetic factors, to improve risk stratification and guide treatment decisions for PMF patients.
Area of Science:
- Hematology
- Oncology
- Medical Prognostics
Background:
- Primary myelofibrosis (PMF) is a Philadelphia chromosome-negative myeloproliferative neoplasm with highly variable clinical outcomes.
- Accurate prognostication is crucial for managing PMF heterogeneity and guiding treatment, including hematopoietic stem cell transplantation eligibility.
Purpose of the Study:
- To review established and emerging prognostic models for primary myelofibrosis.
- To provide a practical framework for risk stratification in PMF and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Main Methods:
- Review of widely adopted prognostic scoring systems for PMF.
- Inclusion of models incorporating clinical, molecular, and cytogenetic features.
- Discussion of models for both primary PMF and secondary myelofibrosis.
Main Results:
- Several prognostic models exist, evolving from clinical-only to integrated molecular and cytogenetic assessments.
- Models like IPSS, DIPSS, MIPSS70, and others offer varying levels of risk stratification.
- Emerging models aim for more comprehensive prognostication in PMF.
Conclusions:
- Prognostic models are essential for managing PMF heterogeneity and guiding therapeutic strategies.
- Contemporary models leveraging molecular and cytogenetic data enhance prognostication accuracy.
- A practical approach to risk stratification aids clinical decision-making in PMF.
